Join us at the SAGES 2025 Annual Meeting

March 12-15 | Long Beach, CA

Satellite Symposium

Advancing Care for Refractory Gastroparesis: Key Findings from a Large, Prospective, 5-Year Study

Friday, March 14 | 12:15 p.m. - 1:15 p.m.
Long Beach Convention Center
Room 203

Lunch will be served

Keynote Speaker

Michael Awad, MD, PhD, MHPE, FACS
Department of Surgery
Washington University School of Medicine
St Louis, MO

Surgical Treatment of Gastroparesis: Evidence and Innovations

Saturday, March 15 | 10:45 a.m. - 10:55 a.m.
Long Beach Convention Center

Promenade 102ABC

Melissa DeSouza, MD
Director of Esophageal Research
Center for Advanced Surgery
The Oregon Clinic
Portland, OR

Guilherme M. Campos, M.D.,
Ph.D., FACS, FASMBS
Professor of Surgery and
Chair, Division of Bariatric and
Gastrointestinal Surgery
Virginia Commonwealth University
Richmond, VA



Enterra® Therapy

Visit us at booth 943

Stop by our booth to learn about the **latest insights in gastroparesis** and **new 5-year data** from the largest, independently conducted study on **Enterra Therapy.**

enterra® medical®

Important Safety Information
Enterra® Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.

Indications for Use: The Enterra Therapy System for gastric electrical stimulation is indicated for use in the treatment of chronic, intractable (drug refractory) nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years.

Contraindications: The Enterra Therapy System is not intended for patients whom the physician determines are not candidates for surgical procedures and/or anesthesia due to physical or mental health conditions. You cannot have diathermy (deep heat treatment from electromagnetic energy) if you have an Enterra device.

Warnings/Precautions/Adverse Events: This system has not been evaluated for pregnant women, for use in patients under the age of 18, or patients over the age of 70. The system may be affected by or adversely affect cardiac devices. Strong sources of electromagnetic interference (EMI) such as from electrocautery, defibrillation/cardioversion, therapeutic ultrasound, radiofrequency (RF)/microwave ablation, or MRI, can result in serious injury, system damage, or operational changes to the system. EMI, postural changes, or other activities may cause shocking or jolting sensations.

The Enterra II System is MR Conditional. This means that patients with the Enterra II System can safely have MRI examinations of some body parts under certain conditions. The conditions for MRI scans will vary with the type of MRI coil. Obtain the latest MRI guidelines by referring to the manuals at www.enterramedical.com/hcp/manuals. Patients on anticoagulation therapy may be at a greater risk for post-operative complications. The use of non-Enterra Medical components with this system may result in damage to Enterra Medical components, loss of therapy, or patient injury. There is the possibility of an allergic or immune system response to the implanted materials. When possible, a physician is to identify and treat any infections prior to surgery. Infections at the implant site almost always require the surgical removal of the implanted system. The lead can become entangled with the bowel or perforate your stomach and cause life-threatening blockage or infections that require immediate medical attention and may require surgery. Patients should avoid activities that may put undue stress on the implanted system components (activities that include sudden, excessive, or repetitive bending, twisting, bouncing, or stretching that can cause component fracture or dislodgement). Adverse events related to the therapy, device, or procedure can include: infection, pain at the surgery site, device components may wear through the skin, bruising at the neurostimulator site, bleeding, loss of therapeutic effect, undesirable change in stimulation (described as a jolting, shocking, or burning sensation), gastrointestinal symptoms and gastrointestinal complications (in that the lead may perforate your stomach or device components may become entangled with or obstruct other internal organs, requiring surgery). The system could stop because of battery depletion or mechanical or electrical problems. Any of these situations may require additional surgery or cause your symptoms to return.

Humanitarian Device: Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated.

For further information, please contact Enterra Medical at info@enterramedical.com.
USA Rx only.

www.enterramedical.com

MKT-PM-02931, Rev A

enterra medical®